Cisplatin Plus Raltitrexed or 5-fluorouracil Concurrent With Radiotherapy for Head and Neck Squamous Cell Cancer
A Multicenter Phase Ⅲ Trial of Cisplatin Plus Raltitrexed or 5-fluorouracil in Concurrence With Intensity-modulated Radiotherapy (IMRT) for the Treatment of Locoregionally Advanced Head and Neck Squamous Cell Cancer
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Xuesong Jiang, M.D.
- Phone Number: 86138517007
- Email: 13851700790@126.com
Study Locations
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210009
- Recruiting
- Jiangsu Cancer Hospital
-
Contact:
- Xuesong Jiang, M.D.
- Email: 13851700790@126.com
-
Sub-Investigator:
- Xuesong Jiang, M.D.
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Pathologically confirmed untreated head and neck squamous cell cancer patients
- 18-70 years
- Clinical stage: T3-4N0-3M0 or T1-4N1-3M0
- Hematologic function: WBC ≥ 4.0×109/L, PLT ≥ 80×109/L, Hb ≥ 10mg/dL
- Renal function: Cr ≤ 1.25×UNL
- Hepatic function: BIL ≤ 1.5×UNL, ALT/AST ≤ 2.5×UNL
- ECOG ≤ 1
- Woman and man of childbearing age must adopt contraception
- With written consent
Exclusion Criteria:
- Malignant history
- Pregnant or lactating women
- With other severe diseases (blood, liver ,kidney or heart diseases)
- Subjects not suitable for chemo-radiotherapy
- Without written consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Raltitrexed plus cisplatin
Raltitrexed plus cisplatin and IMRT
|
Patients will receive IMRT and concurrent raltitrexed and cisplatin
All patients will receive concurrent cisplatin.
All patients will receive IMRT
|
|
Active Comparator: 5-fluorouracil plus cisplatin
5-fluorouracil plus cisplatin and IMRT
|
All patients will receive concurrent cisplatin.
All patients will receive IMRT
Patients will receive IMRT and concurrent 5-Fu and cisplatin
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Progression-free survival (PFS)
Time Frame: 36 months
|
36 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Overall Survival (OS)
Time Frame: 36 months
|
36 months
|
|
Locoregional and distant control rate
Time Frame: 36 months
|
36 months
|
|
Percentage of participants experiencing grade 3-5 adverse events(AEs)
Time Frame: 36 months
|
36 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Xia He, M.D., Jiangsu Cancer Institute & Hospital
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Carcinoma, Squamous Cell
- Neoplasms, Squamous Cell
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Folic Acid Antagonists
- Cisplatin
- Fluorouracil
- Raltitrexed
Other Study ID Numbers
Other Study ID Numbers
- 2014NL-035
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.